Description: Ligand discovers, develops and markets new drugs for critical unmet medical needs in the areas of cancer, pain, skin diseases, hormone-related diseases, osteoporosis, metabolic disorders, cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology related to intracellular receptors.
Home Page: www.ligand.com
555 Heritage Drive
Jupiter,
FL
33458
United States
Phone:
858 550 7500
Officers
| Name | Title |
|---|---|
| Mr. Todd C. Davis Ph.D. | CEO & Director |
| Mr. Octavio Espinoza | Chief Financial Officer |
| Mr. Andrew T. Reardon J.D. | Chief Legal Officer & Secretary |
| Mr. Paul J. Hadden | Senior Vice President of Investments & Business Development |
| Michael Jeong | Head of Investor Relations |
| Mr. Todd Pettingill C.F.A. | Director of Corporate Development |
| Dr. Keith Marschke | Senior Vice President of Biology & Scientific Affairs |
| Dr. Vincent D. Antle | Senior Vice President of Technical Operations & QA - Capitsol |
| Mr. Patrick Lucy | Senior VP & CBO Protein Expression Business |
| Dr. Karen R. Reeves M.D. | Senior VP of Investments & Head of Clinical Strategy |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 58 |